Wskazania do niestandardowego stosowania profilaktyki przeciwzakrzepowej u chorych z rakiem jajnika – opis dwóch przypadków i przegląd piśmiennictwa

• Authors: Zbigniew Krasiński , Radosław Lisiecki , Aleksandra Krasińska

Title variants

EN

Indications for a non-standard use of thromboprophylaxis in patients with ovarian cancer – two case reports and a literature review

• Languages of publication: EN PL

Abstracts

EN

The authors report two cases of gynecologic malignancy in women receiving different thromboprophylactic regimens. Presently, everyday clinical problems are not always solved based on the well-established standards for the preventive management in venous thromboembolism. The paper presents a review of the literature on the principles for the use of lowmolecular- weight heparins in patients undergoing oncologic surgeries, with particular attention to the aspects of thrombotic risk and suggestions on non-standard management in cases not included in the guidelines. The recommendations of scientific associations, due to their inertia, are released with a delay relative to research, and may present inconsistent views due to the differences in publication timing. This article is to raise readers’ awareness of the scale of the problem and the importance of the effects of thromboembolic complications on prognosis in cancer. The need to assess the risk of these complications at every stage of cancer treatment should be emphasized. Additionally, risk assessment can be used as an opportunity to educate patients in this aspect.

PL

Autorzy opisują dwa przypadki kobiet z nowotworami narządów rodnych, u których zastosowano różne schematy profilaktyki przeciwzakrzepowej. Obecnie dobrze opracowane standardy postępowania zapobiegającego żylnej chorobie zatorowo-zakrzepowej nie zawsze są w stanie rozwiązać problemy kliniczne dnia codziennego. W pracy dokonano przeglądu piśmiennictwa dotyczącego zasad stosowania heparyn drobnocząsteczkowych u chorych poddawanych zabiegom onkologicznym, zwracając uwagę na aspekty ryzyka zakrzepowego oraz sugerując niestandardowe postępowanie w przypadkach, które nie są uwzględniane w wytycznych. Zalecenia towarzystw naukowych ze względu na swoją inercję ukazują się z pewnym opóźnieniem w stosunku do szeregu prowadzonych badań, a niekiedy ze względu na różny czas publikacji w pewnych zagadnieniach przedstawiają niespójne poglądy. Niniejszy artykuł ma uświadomić czytelnikom skalę problemu, wagę wpływu powikłań zatorowo-zakrzepowych na rokowania w chorobie nowotworowej. Należy podkreślać konieczność oceny ryzyka występowania tych powikłań na każdym etapie leczenia onkologicznego. Dodatkowo ocenę ryzyka można wykorzystać jako okazję do edukacji chorych w tym aspekcie.

Keywords

EN

cancer; deep vein thrombosis; rak; venous thromboembolism; zakrzepica żył głębokich; żylna choroba zatorowo-zakrzepowa

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Current Gynecologic Oncology
• Year: 2016
• Volume: 14
• Issue: 1
• Pages: 53-62

Contributors

author

Zbigniew Krasiński

• Klinika Chirurgii Ogólnej i Naczyń, Uniwersytet Medyczny w Poznaniu, Poznań, Polska

author

Radosław Lisiecki

• Pleszewskie Centrum Medyczne w Pleszewie Sp. z o.o., Pleszew, Polska

author

Aleksandra Krasińska

• Studenckie Koło Naukowe Mikrobiologii, Uniwersytet Medyczny w Poznaniu, Poznań, Polska

References

• 1. Riess H: Hemostasis in malignancy. Biomedical Progress 1997; 10: 51–54.
• 2. Luzzatto G, Schafer AI: The prethrombotic state in cancer. Semin Oncol 1990; 17: 147–159.
• 3. Bick RL: Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 1992; 18: 353–372.
• 4. Rickles FR, Edwards RL: Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983; 62: 14–31.
• 5. Levitan N, Dowlati A, Remick SC et al.: Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285–291.
• 6. Sørensen HT, Mellemkjaer L, Olsen JH et al.: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846–1850.
• 7. Hirsh J: From unfractionated heparins to low molecular weight heparins. Acta Chir Scand Suppl 1990; 556: 42–50.
• 8. Kucher N, Spirk D, Baumgartner I et al.: Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Ann Oncol 2010; 21: 931–935.
• 9. Lyman GH: Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer 2009; 115: 5637–5650.
• 10. Tapson VF, Decousus H, Pini M et al.; IMPROVE Investigators: Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007; 132: 936–945.
• 11. Cohen AT, Tapson VF, Bergmann JF et al.; ENDORSE Investigators: Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational crosssectional study. Lancet 2008; 371: 387–394.
• 12. Kakkar AK, Levine M, Pinedo HM et al.: Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 2003; 8: 381–388.
• 13. Krasiński Z, Krasińska B, Sanocki M: Nowotwory i żylna choroba zatorowo-zakrzepowa – dlaczego powinniśmy stosować heparyny drobnocząsteczkowe? Onkol Pol 2010; 13: 97–106.
• 14. Morgan MA, Iyengar TD, Napiorkowski BE et al.: The clinical course of deep vein thrombosis in patients with gynecologic cancer. Gynecol Oncol 2002; 84: 67–71.
• 15. Kakkar AK, Levine MN, Kadziola Z et al.: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004; 22: 1944–1948.
• 16. Lee AY, Levine MN, Baker RI et al.; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators: Lowmolecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153.
• 17. Krasiński Z, Szpurek D, Staniszewski R et al.: The value of extended preoperative thromboprophylaxis with dalteparin in patients with ovarian cancer qualified to surgical treatment. Int Angiol 2014; 33: 365–371.
• 18. Lyman GH, Khorana AA, Falanga A et al.; American Society of Clinical Oncology: American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490–5505.
• 19. Geerts WH, Bergqvist D, Pineo GF et al.; American College of Chest Physicians: Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl): 381S–453S.
• 20. Satoh T, Oki A, Uno K et al.: High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer 2007; 97: 1053–1057.
• 21. Peedicayil A, Weaver A, Li X et al.: Incidence and timing of venous thromboembolism after surgery for gynecological cancer. Gynecol Oncol 2011; 121: 64–69.
• 22. Tateo S, Mereu L, Salamano S et al.: Ovarian cancer and venous thromboembolic risk. Gynecol Oncol 2005; 99: 119–125.
• 23. Rahn DD, Mamik MM, Sanses TV et al.; Society of Gynecologic Surgeons Systematic Review Group: Venous thromboembolism prophylaxis in gynecologic surgery: a systematic review. Obstet Gynecol 2011; 118: 1111–1125.
• 24. von Tempelhoff GF, Dietrich M, Niemann F et al.: Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997; 77: 456–461.
• 25. Lyman GH, Khorana AA, Kuderer NM et al.; American Society of Clinical Oncology Clinical Practice: Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31: 2189–2204.
• 26. Bergqvist D, Agnelli G, Cohen AT et al.; ENOXACAN II Investigators: Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975–980.
• 27. Rasmussen MS, Jorgensen LN, Wille-Jørgensen P et al.; FAME Investigators: Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006; 4: 2384–2390.
• 28. Kakkar VV, Balibrea JL, Martínez-González J et al.; CANBESURE Study Group: Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010; 8: 1223–1229.
• 29. Lausen I, Jensen R, Jorgensen LN et al.: Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg 1998; 164: 657–663.
• 30. Bottaro FJ, Elizondo MC, Doti C et al.: Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A meta-analysis. Thromb Haemost 2008; 99: 1104–1111.
• 31. Huo MH, Muntz J: Extended thromboprophylaxis with lowmolecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review. Clin Ther 2009; 31: 1129–1141.
• 32. Fagarasanu A, Alotaibi GS, Hrimiuc R et al.: Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 2016; 23: 1422–1430.
• 33. Di Nisio M, Porreca E, Ferrante N et al.: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 2012; 2: CD008500.
• 34. Verso M, Agnelli G, Barni S et al.: A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the PROTECHT score. Intern Emerg Med 2012; 7: 291–292.
• 35. Khorana AA, Kuderer NM, Culakova E et al.: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902–4907.
• 36. George D, Agnelli G, Fisher W et al.: Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVEONCO. ASH Annual Meeting Program and Proceedings, 2011.
• 37. Khorana AA, Otten HM, Zwicker JI et al.; Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis: Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH. J Thromb Haemost 2014; 12: 1928–1931.

• Document Type: report